m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05059
 [1]
Non-coding RNA CircSTAG1 ALKBH5  lncRNA       miRNA   circRNA Direct Inhibition m6A modification FAAH FAAH ALKBH5 Demethylation : m6A sites
m6A Modification:
m6A Regulator RNA demethylase ALKBH5 (ALKBH5) ERASER
 Regulator Info 
m6A Target Fatty-acid amide hydrolase 1 (FAAH)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Circ_STAG1 circRNA View Details
Regulated Target RNA demethylase ALKBH5 (ALKBH5) View Details
Crosstalk Relationship ncRNA  →  m6A Inhibition
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary Overexpressed Circ_STAG1 captured ALKBH5 and decreased the translocation of ALKBH5 into the nucleus, leading to increased m6A methylation of fatty acid amide hydrolase (Fatty-acid amide hydrolase 1 (FAAH)) messenger RNA and degradation of FAAH in astrocytes with subsequent attenuation of depressive-like behaviors and astrocyte loss induced by corticosterone in vitro.
Responsed Disease Major depressive disorder ICD-11: 6A70.3
 Disease Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Fatty-acid amide hydrolase 1 (FAAH) 10 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name Piperazine urea derivative 2 Patented [2]
Synonyms
PMID26413912-Compound-48
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 18 nM
External Link
TTD: D00ZCD
 Compound Name Carbamoyl oxime derivative 1 Patented [2]
Synonyms
PMID26413912-Compound-29
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 10 nM
External Link
TTD: D0C3OH
 Compound Name Carbamate derivative 6 Patented [2]
Synonyms
PMID26413912-Compound-33
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 0.46 nM
External Link
TTD: D0I6VK
 Compound Name Carbamate derivative 5 Patented [2]
Synonyms
PMID26413912-Compound-32
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
TTD: D0X9GL
 Compound Name Carbamate derivative 4 Patented [2]
Synonyms
PMID26413912-Compound-31
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1 nM
External Link
TTD: D0ZU3R
 Compound Name Ethylaminopyrimidine derivative 1 Patented [2]
Synonyms
PMID26413912-Compound-73
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 3 nM
External Link
CID: 44203832
TTD: D01THA
 Compound Name PMID26413912-Compound-84 Patented [2]
MOA Inhibitor
Activity IC50 < 100 nM
External Link
CID: 91008342
TTD: D0B7CW
 Compound Name Carbamide derivative 1 Patented [2]
Synonyms
PMID26413912-Compound-49
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 320 nM
External Link
CID: 54576693
TTD: D0IA7Z
DrugBank: DB15173
 Compound Name Pyrimidinyl ethylenediamine derivative 1 Patented [2]
Synonyms
PMID26413912-Compound-79
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 60 nM
External Link
CID: 51037025
TTD: D0M1ND
 Compound Name Carbamate derivative 2 Patented [2]
Synonyms
PMID26413912-Compound-27
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 31 nM
External Link
TTD: D0S8TB
References
Ref 1 N(6)-Methyladenosine Modification of Fatty Acid Amide Hydrolase Messenger RNA in Circular RNA STAG1-Regulated Astrocyte Dysfunction and Depressive-like Behaviors. Biol Psychiatry. 2020 Sep 1;88(5):392-404. doi: 10.1016/j.biopsych.2020.02.018. Epub 2020 Feb 28.
Ref 2 Fatty acid amide hydrolase inhibitors: a patent review (2009-2014). Expert Opin Ther Pat. 2015;25(11):1247-66. doi: 10.1517/13543776.2015.1067683. Epub 2015 Sep 28.